Insulet publishes investor presentation outlining Omnipod growth strategy and product pipeline

Reuters2026/08/05 11:26

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Insulet outlined growth plans around Omnipod 5 expansion, a next-generation Omnipod 6 platform, and a fully closed-loop system for type 2 diabetes.
Reported 2025 revenue of USD 2.7 billion, more than 600,000 active customers, and presence in 26 global markets.
Targets U.S. type 1 diabetes penetration of 50%-55% by 2028 from about 40% today; targets U.S. type 2 diabetes penetration of 10%-15% from about 5%.
Pipeline milestones include Omnipod 6 clinical study results with a 510(k) filing, then launch; type 2 fully closed-loop pivotal study start, 510(k) filing, then launch.
Highlighted 2021-2025 financial trajectory, including adjusted operating margin rising to 17.6% and free cash flow of USD 378 million in 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insulet Corporation published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Insulet publishes investor presentation outlining Omnipod growth strategy and product pipeline

You may also like

Crypto prices